CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) May 19, 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and updates from its broad portfolio will be presented at the 2021 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held June 4 â 8, 2021.
âWe are pleased to share updates from our growing clinical portfolio across solid tumors and hematologic malignancies at this yearâs ASCO, including multiple novel combinations of tislelizumab with our investigational Fc-competent anti-TIGIT-antibody ociperlimab and other therapeutic agents, and the ongoing evaluation of our next-generation BTK inhibitor zanubrutinib,â commented Lai Wang, Ph.D., Global Head of R&D at BeiGene. âWe believe that these presentations underscore the breadth and diversity, as well as the remarkable progress and momentum, in BeiGeneâ�
把年龄改小？女演员不服老的背后是容貌焦虑和年龄焦虑！ - 未名空间(mitbbs.com) mitbbs.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mitbbs.com Daily Mail and Mail on Sunday newspapers.
Spotlight on Porosity
Additive manufacturing already has been used in aircraft production for years but only in a limited way to fabricate ductwork, interior components, and other non-critical parts because of the potential for defects that can occur in final parts.
To help remedy this limitation, Sun and his team focused on the set-up of laser power and scan speed and how they interact, researchers said. One of the specific areas of research was porosity, which is when parts come out of the manufacturing process with tiny holes.
Porosity defects are a key challenge for applications such as aircraft wings that can fail under stress and fatigue. Some porosity is associated with deep and narrow vapor depressions called keyholes, which occur under high-power, low-scan-speed laser melting conditions, researchers said.